文献速递乳腺癌放疗放疗物理与技术

城市癌症中心开展术中放射治疗的经验

Experience with intraoperative radiation therapy in an urban cancer center.
PubMed 文献 · Radiat Oncol · 2023-07-25

该研究报道了某城市癌症中心自2018年起使用Intrabeam低能50kVp X线对选择性乳腺癌病例实施术中放射治疗(IORT)的早期结果。2018年1月至2021年12月共评估181例临床0-IIA期ER阳性乳腺癌患者,最终167例患者共172个部位接受IORT,中位随访27.9个月(范围0.7-54.8个月)期间出现3例局部复发(1.6%)。作者结论认为IORT对其人群是安全且以患者为中心的局部辅助放疗方式,长期疗效仍需通过持续随访评估。

要点

  • 167例患者共172个部位接受IORT,160/167(95.8%)在初次诊断手术时进行。
  • 16/167(9.6%)因切缘阳性行IORT后再切除,23/167(13.8%)最终接受全乳±淋巴结辅助放疗。
  • 中位随访27.9个月(范围0.7-54.8个月)出现3例局部复发(1.6%)。

核心结论

  • 作者认为IORT对其人群是安全且以患者为中心的局部辅助放疗方式,该人群中较长程外照射放疗的依从性可能存在问题。
  • 长期疗效仍需通过持续随访评估。
  • 在COVID-19时代及之后,IORT因大幅减少毒性和患者就诊次数而成为越来越有吸引力的选择。

研究设计与样本

  • 2018年起采用Intrabeam低能50kVp X线建立IORT实践,患者前瞻性纳入机构审查委员会批准的登记试验(IRB编号2018-9409)。
  • 登记方案允许ER阳性、1-2级DCIS≤2.5 cm或浸润性疾病≤3.5 cm且年龄至少45岁的患者接受IORT。
  • 2018年1月至2021年12月共评估181例临床0-IIA期ER阳性乳腺癌患者,最终167例患者共172个部位接受IORT。

主要发现

  • 多数患者(160/167;95.8%)在初次诊断和手术时接受IORT。
  • 16/167(9.6%)因切缘阳性在IORT后行再切除。
  • 23/167(13.8%)最终接受全乳±淋巴结辅助放疗,主要原因为最终病理发现前哨淋巴结阳性(12/23;52%),其他原因包括DCIS切缘近(3/23;13%)、肿瘤大小(3/23;4.3%)和多因素(5/23;17.4%)。
  • 5例(3%)出现伤口裂开的术后并发症。
  • 中位随访27.9个月(范围0.7-54.8个月)出现3例局部复发(1.6%)。

关键数值与推荐

  • 登记方案允许IORT的条件为ER阳性、1-2级DCIS≤2.5 cm或浸润性疾病≤3.5 cm且患者年龄至少45岁。

临床怎么用

  • 作者认为IORT是安全且以患者为中心的局部辅助放疗方式,适用于较长程外照射放疗依从性可能存在问题的人群。
  • 作者认为长期疗效仍需通过持续随访评估。
  • 作者认为在COVID-19时代及之后,IORT因大幅减少毒性和患者就诊次数而成为越来越有吸引力的选择。

局限性

  • 长期疗效仍需通过持续随访评估。
  • 早期结果报告,随访时间有限(中位随访27.9个月,范围0.7-54.8个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVE: Intra-operative radiation therapy (IORT) is a newer partial breast irradiation technique that has been well studied in 2 large randomized trials, the TARGIT-A and ELIOT trials. We initiated our IORT program in 2018 in the context of a registry trial, and aim to report our early results thus far. METHODS: We instituted an IORT practice using Intrabeam® low energy 50kVp x-rays for selected breast cancer cases in 2018. Patients were enrolled on our institutional registry protocol which allowed for IORT in ER + patients with grade 1-2 DCIS ≤ 2.5 cm or invasive disease ≤ 3.5 cm in patients of at least 45 years of age. RESULTS: Between January 2018 and December 2021, 181 patients with clinical stage 0-IIA ER + breast cancer were evaluated. One hundred sixty-seven patients ultimately received IORT to 172 sites. The majority of patients received IORT at the time of initial diagnosis and surgery (160/167; 95.8%). Re-excision post IORT occurred in 16/167 patients (9.6%) due to positive margins. Adjuvant RT to the whole breast +/- LN was ultimately given to 23/167 (13.8%) patients mainly due to positive sentinel LN found on final pathology (12/23; 52%); other reasons were close margins for DCIS (3/23; 13%), tumor size (3/23; 4.3%), and multifactorial (5/23; 17.4%). Five patients (3%) had post-operative complications of wound dehiscence. There were 3 local recurrences (1.6%) at a median follow-up of 27.9 months (range: 0.7- 54.8 months). CONCLUSIONS: IORT has been proven to be a safe and patient-centered form of local adjuvant RT for our population, in whom compliance with a longer course of external beam radiation can be an issue. Long term efficacy remains to be evaluated through continued follow up. In the era of COVID-19 and beyond, IORT has been an increasingly attractive option, as it greatly minimizes toxicities and patient visits to the clinic. TRIAL REGISTRATION: All patients were prospectively enrolled on an institutional review board-approved registry trial (IRB number: 2018-9409).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Andraos TY, Skalina KA, Feldman S, et al. Experience with intraoperative radiation therapy in an urban cancer center. Radiat Oncol. 2023. PMID: 37491260. doi:10.1186/s13014-023-02299-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。